The pharmaceutical company Eczacibasi Group plans to invest over EUR 250m in its operations, create more than 1,500 new jobs, and reach an annual turnover of over EUR 150m in 2022 when it celebrates its 80th anniversary, according to Atalay Gumrah, CEO of Eczacibasi. “We’ll primarily develop our R&D activities in nuclear medicine and invest...
Latest News:
The CAD is big and its financing is bad!
To what extent does the misery index influence voters’ choices?
AI and beyond
Budget deficit risk of around 7% of GDP
Tourism revenues rise higher than the number of tourists
Need for anchor
Patents with technological advances in the automotive ecosystem
Let’s estimate FX rates…
Inflation soared while the policy rate was lowered
Famous banks’ election expectations
Energy and gold don’t explain the CAD
Levent Kafkasli becomes GM of GAP Insaat
Global tension: Is it decision time for Turkey?
When you don’t learn from a mistake from 30 years ago
UNDP sends containers to the quake-hit region
Annualized foreign trade deficit tripled in 1.5 years
Fire circle
KKM, liraization: Fiddlesticks!
Capacity usage down contrary to real sector confidence
Home
Eczacibasi Group